Valiant Laboratories Limited's Board of Directors, at its meeting held on Thursday, May 14, 2026, approved the reappointment of its Internal Auditor and Cost Auditor for the financial year 2026-27. The decisions were taken pursuant to the provisions of the Companies Act, 2013 and the applicable rules thereunder, and disclosed to the stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board meeting commenced at 03:30 P.M. and concluded at 05:30 P.M.

Auditor Reappointments for FY 2026-27

The Board approved the reappointment of both its Internal Auditor and Cost Auditor with effect from May 14, 2026. The key details of the appointments are presented below:

Profiles of Appointed Firms

Internal Auditor — Rajesh Chheda & Co.

Rajesh Chheda & Co., Chartered Accountants, brings extensive experience across multiple professional domains. The firm's areas of expertise include:

• Internal and Statutory Audit
• Tax Audit Services
• Corporate Consultancy
• Litigation Support Services
• Strategic Financial Planning & Advisory

Cost Auditor — Ketki D. Visariya & Co.

Ketki D. Visariya & Co. is led by CMA Ketki D. Visariya as proprietor. The firm has carried out cost audits across a wide range of industries, including:

• Pharmaceuticals
• Electronic Machinery
• Chemicals
• Construction
• Gems & Jewellery
• Telecommunication
• Textiles & Garments
• Pipes & Fittings

Regulatory Compliance

The disclosures pertaining to these appointments have been made in accordance with Regulation 30 read with Schedule III of the Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The intimation has also been uploaded on the Company's website at www.valiantlabs.in . The announcement was signed by Akshay Gangurde, Company Secretary & Compliance Officer of Valiant Laboratories Limited.

Valiant Laboratories Limited has formally announced the resignation of its Quality Control Manager, Mr. Bhanudas D. Patil, through an official regulatory filing. The resignation was submitted on April 22, 2026, with immediate effect from the closure of business hours on the same date.

Regulatory Compliance and Filing Details

The company has notified both BSE Limited and National Stock Exchange of India Limited about this senior management personnel change, pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary & Compliance Officer Akshay Gangurde signed the official communication on April 23, 2026.

Management Transition Details

According to the formal resignation letter, Mr. Bhanudas D. Patil cited personal commitments as the reason for stepping down from his position. The resignation represents a significant change in the company's quality control leadership structure, as the QC Manager role is critical for overseeing quality assurance processes and regulatory compliance activities.

Quality Control Department Impact

In his resignation letter, Mr. Patil expressed gratitude for the opportunity provided to continue contributing to the organization after his retirement. He acknowledged the support and cooperation extended by the management and colleagues during his tenure. The Quality Control Manager position holds significant responsibility within pharmaceutical operations, ensuring product quality standards and regulatory compliance.

The company has completed the necessary relieving formalities as indicated in the official documentation. This management change follows standard corporate governance practices, with proper disclosure to stakeholders and regulatory authorities as required under SEBI guidelines.